US › Healthcare

NervGen Pharma Corp. (NGEN)

US · Healthcare · Biotechnology

$1.59-1.85%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-30.0M

EPS

$-0.37

EPS estimate

$-0.09

EPS came in at -0.37 against a street estimate of -0.09 — a miss of 311.1%.

Key statistics

Market cap

$171.0M

Forward P/E

0.0

P/B

17.12

Book value

$0.11

EPS (TTM)

$-0.57

52-week high

$6.30

52-week low

$1.55

50-day MA

$1.94

200-day MA

$3.06

Beta

0.82

Analyst view

Analysts rate NervGen Pharma Corp. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $10.00.

Shareholding

Insiders

15.63%

Institutions

11.22%

Largest institutional holders

Fund	Stake
Empery Asset Management, LP	3.72%
Rock Springs Capital Management LP	1.12%
Dafna Capital Management LLC	0.98%
Ghisallo Capital Management LLC	0.93%
Armistice Capital, LLC	0.63%
LMR Partners LLP	0.56%
Marshall Wace Asset Management Ltd	0.41%
UBS Group AG	0.35%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NervGen Pharma Corp. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.